Vaxart Publishes Positive Data for its Oral Bivalent Norovirus Candidate in Lactating Women and Their Infants

Rhea-AI Summary

Vaxart (OTCQX: VXRT) published Phase 1, double-blind, placebo-controlled data showing a single-dose oral bivalent norovirus vaccine was safe and well-tolerated in lactating women and induced norovirus-specific antibodies in serum and breast milk.

The study reported norovirus-specific IgA in breastfed infants' stool that correlated with breast milk IgA, suggesting passive transfer of mucosal immunity to infants. Results were published in npj Vaccines on Jan 15, 2026.

Positive

• Phase 1 readout: vaccine induced norovirus-specific antibodies in serum and breast milk
• Infant signal: norovirus-specific IgA detected in breastfed infants' stool
• Safety: vaccine described as safe and well-tolerated in postpartum, breastfeeding women
• Peer-reviewed: findings published in npj Vaccines

Negative

• Early-stage evidence: Phase 1 results do not establish clinical efficacy in infants or larger populations
• Unspecified trial size: publication and release do not state participant numbers or powering for efficacy

Key Figures

Clinical trial ID: NCT07254728 US annual norovirus cases: 21 million people Children under 5 infected: 15% +3 more

6 metrics

Clinical trial ID NCT07254728 Double-blind, placebo-controlled Phase 1 trial in lactating women

US annual norovirus cases 21 million people Estimated yearly infections in the United States

Children under 5 infected 15% Share of US children under age 5 contracting norovirus annually

Parents missing work 3 million Sets of parents missing work yearly due to child norovirus illness

Average work days lost 2.2 days Average days parents miss work per norovirus episode

US annual disease burden $10.6 billion Economic burden of norovirus in the United States

Market Reality Check

Price: $0.5490 Vol: Volume 1,524,945 is 18% a...

normal vol

$0.5490 Last Close

Volume Volume 1,524,945 is 18% above 20-day average 1,296,424. normal

Technical Trading above 200-day MA 0.40 with price at 0.549, about mid-range of 52-week band.

Peers on Argus

VXRT gained 3.57% while peers were mixed: XBIT and IFRX rose, CNTB and HLVX slip...

VXRT gained 3.57% while peers were mixed: XBIT and IFRX rose, CNTB and HLVX slipped, ORMP advanced. The pattern points to a stock-specific reaction rather than a coordinated biotech move.

Historical Context

5 past events · Latest: Jan 08 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 08	Investor forum	Neutral	+41.7%	Participation by senior leadership at Global BioInnovation Forum.
Nov 13	Earnings & update	Positive	+11.0%	Q3 2025 results plus Dynavax collaboration and COVID-19 trial progress.
Nov 07	Conference calls	Neutral	+7.2%	Announcements of upcoming earnings call and stockholder fireside chat.
Oct 20	Clinical presentation	Positive	-1.4%	IDWeek 2025 data on second‑generation oral bivalent norovirus vaccine.
Oct 08	Conference update	Positive	-2.2%	World Vaccine Congress Europe updates on norovirus and COVID-19 pills.

Pattern Detected

VXRT has often shown strong upside after corporate updates, including conferences and business results, with only mild pullbacks on some presentation-focused news.

Recent Company History

Over the past several months, Vaxart has highlighted steady clinical and corporate activity. In October 2025 it showcased its norovirus and COVID-19 pill vaccine programs at major meetings, followed by research presentations on its second‑generation oral bivalent norovirus candidate. In November 2025 it provided Q3 results and a business update, including a Dynavax collaboration and detailed government contract revenue. A January 2026 conference appearance also drew a strong positive price reaction, framing today’s norovirus Phase 1 data as part of an ongoing clinical narrative.

Market Pulse Summary

This announcement highlights Phase 1 data showing that Vaxart’s oral bivalent norovirus vaccine cand...

Analysis

This announcement highlights Phase 1 data showing that Vaxart’s oral bivalent norovirus vaccine candidate in lactating women generated norovirus‑specific antibodies in both serum and breast milk, with infant stool IgA correlating to maternal levels. With no approved norovirus vaccine and an estimated annual US disease burden of $10.6 billion, these findings add to the company’s broader norovirus narrative. Investors may watch for later‑stage trials and additional functional immune data in broader populations.

Key Terms

double-blind, placebo-controlled, phase 1, immunogenicity

4 terms

double-blind medical

"data from a double-blind, placebo-controlled Phase 1 trial evaluating a single-dose"

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

placebo-controlled medical

"data from a double-blind, placebo-controlled Phase 1 trial evaluating a single-dose"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

phase 1 medical

"data from a double-blind, placebo-controlled Phase 1 trial evaluating a single-dose"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

immunogenicity medical

"Topline safety and immunogenicity results in lactating women were initially reported"

Immunogenicity is the ability of a substance, such as a vaccine or medication, to provoke an immune response in the body. It matters to investors because high immunogenicity can affect the effectiveness and safety of a product, potentially leading to increased costs or regulatory challenges. Understanding immunogenicity helps assess the long-term viability and market potential of pharmaceutical and biotech investments.

AI-generated analysis. Not financial advice.

Vaccine was safe and well-tolerated and led to a significant increase in norovirus-specific antibodies in serum and breast milk

Norovirus-specific IgA in infant stool correlated with breast milk IgA, suggesting passive transfer of immunity to breastfed infants and the potential for a new approach to confer mucosal anti-norovirus immunity to a vulnerable population

SOUTH SAN FRANCISCO, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral vaccines based on its proprietary delivery platform, today announced the publication in npj Vaccines of data from a double-blind, placebo-controlled Phase 1 trial evaluating a single-dose, oral bivalent vaccine candidate in post-partum, breastfeeding women (NCT07254728). Topline safety and immunogenicity results in lactating women were initially reported in April 2024; the newly published study additionally shows vaccine-induced functional norovirus-specific antibodies in breastmilk and serum from vaccinated women, and norovirus-specific IgA in the stool of their breastfed infants. A positive correlation between levels of breast milk IgA and infant stool IgA was observed.

“These findings demonstrate that oral vaccination of lactating women led to passive transfer of norovirus-specific antibodies to their infants via breastmilk consumption,” said Sean N. Tucker, Vaxart’s Chief Scientific Officer. “This promising finding could be especially important given that children under the age of five years can experience severe disease from norovirus infection, particularly in under-resourced areas. The passive immunity generated by our oral norovirus vaccine candidate has the potential to protect this highly vulnerable population from infection and illness at a time when their immune systems are still developing.”

There is no approved vaccine against norovirus, which sickens approximately 21 million people in the United States each year, including the 15% of children under age 5 who contract norovirus annually. Approximately 3 million sets of parents are forced by this virus to miss work – approximately 2.2 days on average – to care for their children. The annual disease burden from norovirus is $10.6 billion in the United States alone. Globally, norovirus has become the leading cause of pediatric gastroenteritis in health care settings in countries that have adopted a rotavirus vaccine program.¹ Pediatric deaths in the United States due to norovirus are rare, but they are more common in the developing world.

About the Trial
The Phase 1, multicenter, randomized, double-blind, placebo-controlled single dose, dose-ranging study was designed to evaluate the safety, tolerability, and immunogenicity of an orally administered bivalent GI.1/GII.4 norovirus vaccine in healthy lactating women. The primary outcomes of the study were safety and reactogenicity, and breast milk and serum norovirus-specific IgA; passive transfer of IgA to infants was an exploratory outcome. The Bill & Melinda Gates Foundation provided partial funding for the study.

The study enrolled 76 women 18-43 years of age at five sites in South Africa. Participants were randomized into high- or medium-dose vaccine (n=30 per group) or placebo (n=16). As previously reported, the vaccine was safe and well tolerated, and reports of mild or moderate adverse events (AEs) were similar between the placebo group and each of the vaccine groups; no AEs beyond grade 2 were reported. Results for serum and breastmilk IgA at Day 29 post vaccination were consistent with the prior report. Serum norovirus-specific IgA rose an average of 5.6-fold in response to GI.1 and 4.7 fold in response to GII.4 in the high dose group. Breastmilk norovirus-specific IgA rose on average 4.0 fold in response to G1.1 and 6.0 fold in response to GII.4 in the high dose group (p=0.018 and p=0.004, respectively).

Newly reported data show:

• Elevated levels of GI.1 and GII.4-specific breastmilk IgA in the high dose group compared with placebo were maintained through day 180.
• A consistent trend of increased GI.1 and GII.4-specific IgA was observed in the stool from paired infants of vaccinated women at days 29 and 60.
• A positive association between levels of IgA in maternal breast milk and infant stool, supporting the hypothesis of passive transfer of mucosal immunity.
• Oral vaccination induced functional breast milk and serum antibody responses as assessed with norovirus blocking antibody assays.
• Oral vaccination generated GI.1 and GII.4-specific IgA in saliva and nasal lining fluid in lactating women.
  

“These findings add to the growing body of evidence supporting the safety and efficacy of our oral pill norovirus vaccine candidate,” said James F. Cummings, Vaxart’s Chief Medical Officer. “In June, we reported positive Phase 1 data demonstrating that our second-generation norovirus constructs produced statistically significant increases in GI.1 and GII.4 norovirus blocking antibodies compared with first-generation constructs, supporting their potential for improved protection against infection. In September, we reported data demonstrating that these constructs induced robust increases in fecal IgA, which was shown to be correlated with protection against infection in our previous Phase 2b challenge study. The increased immunogenicity shown by second-generation vaccines may improve the passive transfer of norovirus-specific antibodies to breastfed infants in future studies.”

Pending a partnership or other funding, Vaxart expects to initiate the next clinical trial of its norovirus oral vaccine candidate in 2026.

¹ Shah and Hall, Infect Dis Clin North Am. 2018 Mar; 32(1): 103-118.

About Vaxart 
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Vaxart's strategy, prospects, plans and objectives, results from preclinical and clinical trials and the timing of such results, commercialization agreements and licenses, and beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as "should," "believe," "could," "potential," "will," "expected," “anticipate,” "plan," and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements relating to Vaxart's ability to develop and commercialize its product candidates; Vaxart's expectations regarding clinical results and trial data, and the timing of receiving and reporting such clinical results and trial data; Vaxart’s expected timing for future clinical trials; and Vaxart's expectations with respect to the effectiveness of its product candidates. Vaxart may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement, and/or completion dates for clinical trials, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by regulatory authorities impacting labeling, manufacturing processes, and safety that could affect the availability or commercial potential of any product candidate, including the possibility that Vaxart's product candidates may not be approved by the FDA or non-U.S. regulatory authorities; that a Vaxart collaborator may not attain development and commercial milestones; that Vaxart or its partners may experience manufacturing issues and delays due to events within, or outside of, Vaxart's or its partners' control; difficulties in production, particularly in scaling up initial production, including difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel or key raw materials, and compliance with strictly enforced federal, state, and foreign regulations; Vaxart's ability to obtain sufficient capital to fund its operations on terms acceptable to Vaxart, if at all; the impact of government healthcare proposals and policies; competitive factors; and other risks described in the "Risk Factors" sections of Vaxart's Quarterly and Annual Reports filed with the SEC. Vaxart does not assume any obligation to update any forward-looking statements, except as required by law.

Contact
Vaxart Media and Investor Relations: 
FINN Partners
IR@vaxart.com

FAQ

What did Vaxart (VXRT) announce on January 15, 2026 about its oral norovirus vaccine?

Vaxart published Phase 1 data showing a single-dose oral bivalent vaccine was safe in lactating women and generated norovirus-specific antibodies in breast milk and infant stool.

Does Vaxart's VXRT data show infants were protected from norovirus?

The data show norovirus-specific IgA in infant stool correlated with breast milk IgA, suggesting passive transfer of antibodies, but clinical protection was not established in this Phase 1 study.

Were there safety concerns reported for Vaxart's VXRT oral vaccine in breastfeeding women?

No; the study described the oral vaccine as safe and well-tolerated in postpartum, breastfeeding women.

Where were Vaxart's VXRT Phase 1 results published and when?

The results were published in npj Vaccines and announced on January 15, 2026.

What are the next steps after Vaxart's VXRT Phase 1 publication?

The company will need larger, later-stage trials to confirm efficacy, durability, and broader safety before regulatory approval and use.